US EditionCaliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025 - PressReach
Summary by pressreach.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025 - PressReach
Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world’s largest biotech industry event. For the first time at an international conference, Caliway will share preclinical results on CBL-514’s potential new indication: combined with GLP-1 therapies to prevent post-treatment weight rebound. NEW TAIPEI CITY, June 10, 2025 /PRNewswire/ — Caliway Biopharmaceuticals (TWSE: 6919) announced today its p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
